Singletto's Dr. Lendvay contributed to a New MB Study
The Infection Control & Hospital Epidemiology medical journal has published the peer-reviewed DeMaND study. Singletto’s Dr. Tom Lendvay served as Lead Author.
Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer was just named a “Top Doctor” by Seattle Magazine.
Mike Butler spent over two decades in leadership at Providence Health, growing such from a $2 billion organization to $25 billion. Upon recently retiring, Mike knew he wanted to find ways to continue impacting the lives and health of others. Now at Singletto, Mike is on a mission to bring the novel Singletto technology to market – in healthcare and beyond. But, it’s not just a passion project … upon learning about the technology, Mike felt a moral obligation to get it in as many hands as possible. More with recently retired Providence Health President Mike Butler…
Singletto Advisor Dr. Belinda Heyne shares DeMaND study results on Hospital News.
Dr. Belinda Heyne was recently featured in a CBC piece covering the DeMaND study’s findings and the life-giving potential of dye and light.
The World Health Organization (WHO) just added Methylene Blue and Light as a supported Personal Protective Equipment (PPE) decontamination method in the “Rational use of personal protective equipment for COVID-19 and considerations during severe shortages” interim guidelines.
Arbovirologist, professor, and GWU lab director Dr. Chris Mores has just returned from Africa, supporting local and international field teams in the fight against Ebola in the DRC. Though COVID-19 has taken center stage over the last year, it’s important to remember other deadly viruses haven’t taken a day off. More with Chris Mores on fighting pathogens around the world.
After years of fundamental research on photosensitizers, Belinda Heyne, Ph.D, now applies concepts of photochemistry and photobiology to the fight against pathogens. Her expertise and her lab’s unique ability to measure singlet oxygen directly make her critically important to Singletto’s ongoing research efforts and technology development. More with expert Belinda Heyne.
In collaboration with the WHO, CDC, and a consortium of labs around the world, Singletto founders Drs. Chen, Lendvay and Clark, conducted extensive research on the decontamination effects of the light-activated dye Methylene Blue on viruses, including SARS-CoV-2. The positive results of such study have been pre-published on medRxiv. Watch our video to learn more.
New standard for PPE decontamination discovered
WHO consortium finds Methylene Blue, a light-activated dye, inactivates SARS-CoV-2 (the coronavirus responsible for the COVID-19 pandemic) on masks and PPE gear. DeMaND Study lead author and Singletto co-founder Dr. Thomas Lendvay explains more …
Photodynamic Therapy, light-activated dyes, and singlet oxygen explained. DeMaND Study co-author and Singletto co-founder Dr. James Chen explains the science behind Singletto’s new technologies.
We found answers to the greatest public health challenge of our lifetimes in nature’s most basic technologies: dye and light. The recent WHO DeMaND study concludes that light-activated dyes are an effective, low-cost decontamination method for PPE. Here’s why this can help us overcome the COVID-19 pandemic.
A vaccine alone won’t save us from COVID-19. And while we wait, global PPE shortages and reuse are killing health and frontline workers. Here’s why we need a simple, effective way to decontaminate potentially infected PPE—now.
Dr. Thomas Lenvay develops a method to decontaminate PPE using Methylene Blue and light.
Our founders join a study to decontaminate PPE for healthcare workers.